Stay updated with breaking news from Readiness Pilot. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Catalyst-rich 2024 with multiple clinical data readouts and updates expected for pipeline and discovery programs Phase 2/3 Duravelo-2 registrational trial for BT8009 in metastatic urothelial cancer...
R&D Day on December 14 to provide clinical updates for BT8009, BT5528 and BT7480, and highlight broad capabilities of novel Bicycle® technology Alignment with FDA on expedited development and...
Company's cash and cash equivalents stand at $572.1 million as of September 30, 2023
Program intended to facilitate CMC development for selected therapies with expedited clinical development timeframes to help patients get access sooner ...
